In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.81 a new company low.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Bridgebio Pharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1672 to 1881.

Explain Quick Ratio?
How much Cash & cash equivalents BBIO�s has?
What are BBIO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BBIO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	406.47 %	513.5 %	86.51 %	55.59 %	30.88 %
Y / Y Cash & cash equivalent Change	-4.85 %	73.92 %	-13.75 %	142.54 %	69.04 %
Quick Ratio MRQ	0.81	1.15	2.04	2.98	4.3
BBIO's Total Ranking	# 1881	# 1672	# 1235	# 1002	# 1044
Seq. Current Liabilities Change	9.1 %	183.49 %	32.95 %	23.17 %	32.15 %
Seq. Cash & cash equivalent Change	-23.4 %	60.04 %	-9.05 %	-14.66 %	40.01 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 371
Healthcare Sector	# 669
Overall Market	# 2163

Quick Ratio Statistics
High	Average	Low
23.68	6.35	0.81
(Sep 30 2019)		(Jun 30 2026)

Financial Statements
Bridgebio Pharma Inc 's Current Liabilities	$ 891 Millions	Visit BBIO's Balance sheet
Bridgebio Pharma Inc 's Cash & cash equivalent	$ 720 Millions	Visit BBIO's Balance sheet
Source of BBIO's Sales		Visit BBIO's Sales by Geography

Cumulative Bridgebio Pharma Inc 's Quick Ratio

BBIO's Quick Ratio for the trailling 12 Months

BBIO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	267.05 %	166.79 %	42.85 %	21.65 %	14.61 %
Y / Y Cash & cash equivalent TTM Growth	28.9 %	51.38 %	32.17 %	63.04 %	21.44 %
Quick Ratio TTM	1.31	1.96	3.11	3.86	3.73
Total Ranking TTM	# 781	# 575	# 309	# 316	# 366
Seq. Current Liabilities TTM Growth	47.75 %	84 %	19.65 %	12.84 %	7.4 %
Seq. Cash & cash equivalent TTM Growth	-1.25 %	15.79 %	-3.57 %	16.91 %	15.97 %

Quick ratio ranking by company, industry and sector >> Back to BBIO Financial Strength Comparisons >> Go to Compare BBIO Quick Ratio to its Competitors

News about Bridgebio Pharma Inc Quick Ratio

BridgeBio Pharma Approves Equity Grants and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Approves Equity Grants and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 05, 2024 - BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases, has announced the approval of equity grants to 25 new employees. These grants are in the form of restricted stock units and amount to a total of 123,070 shares of the company s common stock. The compensation committee of BridgeBio s board of directors approved these grants on July 2, 2024.
Under the terms of the grants, one-fourth of the shares underlying each employee s restricted stock units will vest on August 16, 2025. Thereafter, one-twelfth of the remaining shares will vest on a quarterly basis, subject to the employees continued employment with the company. These awards were made under BridgeBio s Amended and Restated 2019 Inducement Equity Plan.

BridgeBio Pharma Receives $1.25 Billion Funding and Grants Inducement Stock Units to Drive Genetic Medicine Development

BridgeBio Pharma Secures Funding and Grants Inducement Stock Units to Expand Workforce
BridgeBio Pharma, a leading biopharmaceutical company, recently announced a significant development in its efforts to advance the treatment of genetic diseases and cancers. The company has secured up to $1.25 billion in capital from Blue Owl and CPP Investments, which will be used to accelerate the development and launch of genetic medicines. In addition, BridgeBio Pharma has granted inducement stock units to nineteen new employees, highlighting its commitment to expanding its talented workforce.
The funding includes $500 million in cash from Blue Owl and CPP Investments. In exchange, the two investors will receive a 5% royalty on future global net sales of acoramidis, one of BridgeBio Pharma s promising drugs. This injection of capital will provide the company with the necessary resources to further its research and development efforts, as well as support the launch of new genetic medicines.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $890.65 millions, cumulative Quick Ratio decreased to 1.31 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Bridgebio Pharma Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents BBIO�s has?
What are BBIO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 434
Healthcare Sector	# 888
Within the Market	# 1881

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.97	3.83	1.25
(Jun 30 2020)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Ars Pharmaceuticals Inc	2.22	$ 143.845 Millions	$ 64.728 Millions
Alnylam Pharmaceuticals Inc	2.19	$ 3,308.147 Millions	$ 1,512.513 Millions
Xeris Biopharma Holdings Inc	2.16	$ 243.494 Millions	$ 112.826 Millions
Ardelyx inc	2.13	$ 281.830 Millions	$ 132.220 Millions
Oragenics Inc	2.12	$ 3.864 Millions	$ 1.822 Millions
Pacira Biosciences inc	2.06	$ 251.031 Millions	$ 122.011 Millions
Genelux Corporation	2.05	$ 29.870 Millions	$ 14.590 Millions
Opko Health Inc	2.01	$ 300.761 Millions	$ 149.367 Millions
Corcept Therapeutics Inc	2.00	$ 308.197 Millions	$ 153.802 Millions
Clene Inc	2.00	$ 9.700 Millions	$ 4.852 Millions
Blue Water Vaccines Inc	2.00	$ 5.942 Millions	$ 2.974 Millions
Vertex Pharmaceuticals Inc	1.99	$ 7,852.400 Millions	$ 3,937.900 Millions
Metavia Inc	1.99	$ 12.636 Millions	$ 6.346 Millions
Connect Biopharma Holdings Limited	1.93	$ 31.500 Millions	$ 16.301 Millions
Amarin Corp Plcuk	1.92	$ 314.850 Millions	$ 164.195 Millions
Mustang Bio inc	1.91	$ 15.150 Millions	$ 7.918 Millions
Therapeuticsmd Inc	1.84	$ 9.189 Millions	$ 5.003 Millions
Fortress Biotech Inc	1.81	$ 196.576 Millions	$ 108.829 Millions
Maravai Lifesciences Holdings Inc	1.77	$ 70.091 Millions	$ 39.519 Millions
Decoy Therapeutics Inc	1.77	$ 8.289 Millions	$ 4.680 Millions
Hyperion Defi inc	1.75	$ 9.637 Millions	$ 5.509 Millions
Verastem Inc	1.75	$ 136.400 Millions	$ 78.130 Millions
Urogen Pharma Ltd	1.74	$ 108.000 Millions	$ 61.915 Millions
Pyxis Oncology Inc	1.72	$ 47.141 Millions	$ 27.474 Millions
Ernexa Therapeutics Inc	1.71	$ 5.028 Millions	$ 2.932 Millions
Lantern Pharma Inc	1.70	$ 7.361 Millions	$ 4.323 Millions
Nuvectis Pharma inc	1.67	$ 22.160 Millions	$ 13.294 Millions
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions

Date modified: 2026-08-12T19:40:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.